[ Michael J. Fox Foundation - Therapeutic Pipeline Program | Research Funding ]
Event details
| Date | 14.05.2020 |
| Category | Call for proposal |
Aim: The Michael J. Fox Foundation (MJFF) funds research to better define, measure, and treat Parkinson’s disease as well as critical tools and other resources to advance that research. The purpose of this Request for Applications (RFA) is to support the development of new treatments and interventions with potential for significant impact for people with Parkinson’s. The Therapeutic Pipeline Program seeks to speed the development of Parkinson’s disease therapeutics with potential for fundamentally altering disease course, significantly improving treatment or management of non-motor or motor symptoms beyond current standards of care. Proposals should focus on strategies with clear impact for people with Parkinson’s and well-defined development plans. This RFP offers two tracks: a pre-clinical track and a clinical track. See the RFP download for the differences between the two.
Note that this cycle, MJFF is particularly interested in early stage drug discovery efforts for novel targets using phenotypic or target-based screening approaches and efforts focused on developing therapeutics that alleviate non-motor symptoms.
Funding: max. $500’000 (preclinical)
max. $2’000’000 (clinical)
Duration: 1-2 years (pre-clinical)
2-3 years (clinical)
Eligibility: U.S. and non-U.S. public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments and eligible agencies of the federal government. Post-doctoral fellows are not eligible to apply as principal investigators.
How to Apply: The pre-proposal is the first step in the application. Pre-proposals must be completed in the online application portal. All pre-proposals received in response to MJFF RFAs will be subjected to review and only applicants whose pre-proposals are determined to best fit criteria as defined in the RFA will be invited to submit full applications. At the full proposal stage, an institutional approval will be required; for assistance, please contact the Research Office.
Deadline (Pre-proposal): May 14, 2020 (5:00 pm EST) (extended from April 23, 2020)
Deadline (Full Application, by invitation): 11 August 2020 (5:00 pm EST)
Further information
Note that this cycle, MJFF is particularly interested in early stage drug discovery efforts for novel targets using phenotypic or target-based screening approaches and efforts focused on developing therapeutics that alleviate non-motor symptoms.
Funding: max. $500’000 (preclinical)
max. $2’000’000 (clinical)
Duration: 1-2 years (pre-clinical)
2-3 years (clinical)
Eligibility: U.S. and non-U.S. public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments and eligible agencies of the federal government. Post-doctoral fellows are not eligible to apply as principal investigators.
How to Apply: The pre-proposal is the first step in the application. Pre-proposals must be completed in the online application portal. All pre-proposals received in response to MJFF RFAs will be subjected to review and only applicants whose pre-proposals are determined to best fit criteria as defined in the RFA will be invited to submit full applications. At the full proposal stage, an institutional approval will be required; for assistance, please contact the Research Office.
Deadline (Pre-proposal): May 14, 2020 (5:00 pm EST) (extended from April 23, 2020)
Deadline (Full Application, by invitation): 11 August 2020 (5:00 pm EST)
Further information
- See the official webpage for more details, or download the RFA
- Find the application portal here
- Participate in the MJFF funding opportunities webinar on 27 March to learn more
- For any other questions, contact the Research Office
Practical information
- General public
- Free